{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:09:52Z","timestamp":1784545792270,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["031A210"],"award-info":[{"award-number":["031A210"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology in Vitro"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.tiv.2018.07.008","type":"journal-article","created":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T06:17:50Z","timestamp":1533795470000},"page":"80-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["In vitro potency determination of botulinum neurotoxin serotype A based on its receptor-binding and proteolytic characteristics"],"prefix":"10.1016","volume":"53","author":[{"given":"Heike A.","family":"Behrensdorf-Nicol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emina","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Bonifas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Klimek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay-Martin","family":"Hanschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Kegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tiv.2018.07.008_bb0005","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","article-title":"Botulinum toxin as a biological weapon: medical and public health management","volume":"28","author":"Arnon","year":"2001","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.tiv.2018.07.008_bb0010","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.tiv.2009.12.018","article-title":"In vitro determination of tetanus toxicity by an endopeptidase assay linked to a ganglioside-binding step","volume":"24","author":"Behrensdorf-Nicol","year":"2010","journal-title":"Toxicol. in Vitro"},{"issue":"52","key":"10.1016\/j.tiv.2018.07.008_bb0015","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1016\/j.vaccine.2013.10.028","article-title":"Binding and cleavage (BINACLE) assay for the functional in vitro detection of tetanus toxin: applicability as alternative method for the safety testing of tetanus toxoids during vaccine production","volume":"31","author":"Behrensdorf-Nicol","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.tiv.2018.07.008_bb0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.toxicon.2015.08.001","article-title":"Clinical differences between botulinum neurotoxin type A and B","volume":"107","author":"Bentivoglio","year":"2015","journal-title":"Toxicon"},{"issue":"2","key":"10.1016\/j.tiv.2018.07.008_bb0025","doi-asserted-by":"crossref","first-page":"114","DOI":"10.14573\/altex.2010.2.114","article-title":"The botulinum neurotoxin LD50 test - problems and solutions","volume":"27","author":"Bitz","year":"2010","journal-title":"ALTEX"},{"issue":"6442","key":"10.1016\/j.tiv.2018.07.008_bb0030","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/365160a0","article-title":"Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25","volume":"365","author":"Blasi","year":"1993","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.tiv.2018.07.008_bb0035","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1021\/ac050485f","article-title":"From the mouse to the mass spectrometer: detection and differentiation of the endoproteinase activities of botulinum neurotoxins A-G by mass spectrometry","volume":"77","author":"Boyer","year":"2005","journal-title":"Anal. Chem."},{"issue":"10","key":"10.1016\/j.tiv.2018.07.008_bb0040","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/toxins4100913","article-title":"Clinical uses of botulinum neurotoxins: current indications, limitations and future developments","volume":"4","author":"Chen","year":"2012","journal-title":"Toxins (Basel)"},{"issue":"1","key":"10.1016\/j.tiv.2018.07.008_bb0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/dsu.12071","article-title":"Comparative study of biological activity of four botulinum toxin type a preparations in mice","volume":"39","author":"Chung","year":"2013","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.tiv.2018.07.008_bb0050","first-page":"2113","article-title":"Botulinum toxin type A for injection: European Pharmacopoeia 9.2","author":"Council of Europe","year":"2017","journal-title":"Monograph"},{"key":"10.1016\/j.tiv.2018.07.008_bb0055","first-page":"2581","article-title":"Botulinum toxin type B for injection: European pharmacopoeia 9.2","author":"Council of Europe","year":"2017","journal-title":"Monograph"},{"issue":"7","key":"10.1016\/j.tiv.2018.07.008_bb0060","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1083\/jcb.200305098","article-title":"Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells","volume":"162","author":"Dong","year":"2003","journal-title":"J. Cell Biol."},{"issue":"5773","key":"10.1016\/j.tiv.2018.07.008_bb0065","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1123654","article-title":"SV2 is the protein receptor for botulinum neurotoxin A","volume":"312","author":"Dong","year":"2006","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.tiv.2018.07.008_bb0070","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1128\/AEM.01664-12","article-title":"Detection of botulinum neurotoxin serotype A, B, and F proteolytic activity in complex matrices with picomolar to femtomolar sensitivity","volume":"78","author":"Dunning","year":"2012","journal-title":"Appl. Environ. Microbiol."},{"issue":"4","key":"10.1016\/j.tiv.2018.07.008_bb0075","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.toxicon.2010.12.019","article-title":"Studies on the dissociation of botulinum neurotoxin type A complexes","volume":"57","author":"Eisele","year":"2011","journal-title":"Toxicon"},{"issue":"11","key":"10.1016\/j.tiv.2018.07.008_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049516","article-title":"Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay","volume":"7","author":"Fern\u00e1ndez-Salas","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tiv.2018.07.008_bb0085","author":"German Federal Institute for Risk Assessment"},{"issue":"1","key":"10.1016\/j.tiv.2018.07.008_bb0090","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/mr.46.1.86-94.1982","article-title":"Bacterial toxins: a table of lethal amounts","volume":"46","author":"Gill","year":"1982","journal-title":"Microbiol. Rev."},{"key":"10.1016\/j.tiv.2018.07.008_bb0095","first-page":"21","article-title":"Assembly and function of the botulinum neurotoxin progenitor complex","volume":"364","author":"Gu","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.tiv.2018.07.008_bb0100","series-title":"Validation of Analytical Procedures: Text and Methodology. Harmonized Tripartite Guideline Q2(R1)","article-title":"International conference on harmonization of technical requirements for registration of pharmaceuticals for human use","author":"ICH","year":"2005"},{"issue":"1","key":"10.1016\/j.tiv.2018.07.008_bb0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nsb879","article-title":"Translocation of botulinum neurotoxin light chain protease through the heavy chain channel","volume":"10","author":"Koriazova","year":"2003","journal-title":"Nat. Struct. Biol."},{"issue":"10","key":"10.1016\/j.tiv.2018.07.008_bb0110","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.bbagen.2012.06.006","article-title":"Trimethylamine N-oxide suppresses the activity of the actomyosin motor","volume":"1820","author":"Kumemoto","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"5","key":"10.1016\/j.tiv.2018.07.008_bb0115","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1006\/jmbi.1999.2945","article-title":"Sequence homology and structural analysis of the clostridial neurotoxins","volume":"291","author":"Lacy","year":"1999","journal-title":"J. Mol. Biol."},{"issue":"10","key":"10.1016\/j.tiv.2018.07.008_bb0120","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/2338","article-title":"Crystal structure of botulinum neurotoxin type A and implications for toxicity","volume":"5","author":"Lacy","year":"1998","journal-title":"Nat. Struct. Biol."},{"issue":"1","key":"10.1016\/j.tiv.2018.07.008_bb0125","article-title":"Structural and Functional Interactions between transient receptor potential vanilloid subfamily 1 and botulinum neurotoxin serotype A","volume":"11","author":"Li","year":"2016","journal-title":"PLoS ONE"},{"issue":"23","key":"10.1016\/j.tiv.2018.07.008_bb0130","doi-asserted-by":"crossref","first-page":"8476","DOI":"10.1073\/pnas.1403224111","article-title":"Microscopic insights into the protein-stabilizing effect of trimethylamine N-oxide (TMAO)","volume":"111","author":"Ma","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tiv.2018.07.008_bb0135","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/0041-0101(96)00070-0","article-title":"Therapeutic botulinum type a toxin: factors affecting potency","volume":"34","author":"McLellan","year":"1996","journal-title":"Toxicon"},{"issue":"1","key":"10.1016\/j.tiv.2018.07.008_bb0140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-0036-1571953","article-title":"Botulinum toxin treatment of neuropathic pain","volume":"36","author":"Mittal","year":"2016","journal-title":"Semin. Neurol."},{"issue":"10","key":"10.1016\/j.tiv.2018.07.008_bb0145","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.tim.2004.08.002","article-title":"Presynaptic receptor arrays for clostridial neurotoxins","volume":"12","author":"Montecucco","year":"2004","journal-title":"Trends Microbiol."},{"issue":"8","key":"10.1016\/j.tiv.2018.07.008_bb0150","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1177\/1087057110374996","article-title":"The osmolyte trimethylamine N-oxide (TMAO) increases the proteolytic activity of botulinum neurotoxin light chains A, B, and E: implications for enhancing analytical assay sensitivity","volume":"15","author":"Nuss","year":"2010","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.tiv.2018.07.008_bb0155","series-title":"Manual of diagnostic tests and vaccines for terrestrial animals","first-page":"25","author":"OIE (World Organisation for Animal Health)","year":"2004"},{"issue":"8","key":"10.1016\/j.tiv.2018.07.008_bb0160","article-title":"Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction","volume":"4","author":"P1","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tiv.2018.07.008_bb0165","author":"Pharma"},{"issue":"1","key":"10.1016\/j.tiv.2018.07.008_bb0170","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1073\/pnas.0609713104","article-title":"Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept","volume":"104","author":"Rummel","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.tiv.2018.07.008_bb0175","doi-asserted-by":"crossref","first-page":"E65","DOI":"10.3390\/toxins8030065","article-title":"Conversion Ratio between Botox\u00ae, Dysport\u00ae, and Xeomin\u00ae in Clinical Practice","volume":"8","author":"Scaglione","year":"2016","journal-title":"Toxins (Basel)"},{"issue":"32","key":"10.1016\/j.tiv.2018.07.008_bb0180","doi-asserted-by":"crossref","first-page":"23784","DOI":"10.1016\/S0021-9258(20)80452-9","article-title":"Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E","volume":"268","author":"Schiavo","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.tiv.2018.07.008_bb0185","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1124\/jpet.103.058149","article-title":"The role of the interchain disulfide bond in governing the pharmacological actions of botulinum toxin","volume":"308","author":"Simpson","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tiv.2018.07.008_bb0190","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.3390\/toxins7124861","article-title":"Generation and Characterization of Six Recombinant Botulinum Neurotoxins as Reference Material to Serve in an International Proficiency Test","volume":"7","author":"Weisemann","year":"2015","journal-title":"Toxins"},{"key":"10.1016\/j.tiv.2018.07.008_bb0195","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.tiv.2016.03.011","article-title":"In vitro potency determination of botulinum neurotoxin B based on its receptor-binding and proteolytic characteristics","volume":"34","author":"Wild","year":"2016","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.tiv.2018.07.008_bb0200","author":"World Health Organization"}],"container-title":["Toxicology in Vitro"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233318303606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233318303606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:30:06Z","timestamp":1760135406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887233318303606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":40,"alternative-id":["S0887233318303606"],"URL":"https:\/\/doi.org\/10.1016\/j.tiv.2018.07.008","relation":{},"ISSN":["0887-2333"],"issn-type":[{"value":"0887-2333","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro potency determination of botulinum neurotoxin serotype A based on its receptor-binding and proteolytic characteristics","name":"articletitle","label":"Article Title"},{"value":"Toxicology in Vitro","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tiv.2018.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}